NCT04382157

Magnesium Replacement and Hyperglycemia After Kidney Transplantation

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Oslo University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The insulin receptor is dependent on magnesium and hypomagnesemia is associated with increased insulin resistance and decreased insulin secretion and action. Recent data suggest that hypomagnesemia may play a role in development of type 2 diabetes. Kidney transplantation patients have low plasma magnesium levels, partly due to treatment with calcineurin inhibitors. However, the role of magnesium in the development of post-transplant diabetes mellitus (PTDM) is unclear. The present study addresses, whether hypomagnesemia is feasible to reverse by oral administration of magnesium. The investigators wish to investigate whether oral magnesium supplementation is sufficient to increase magnesium levels in kidney transplant recipients, and if supplementation improves glycemic parameters as measured by an oral glucose tolerance test (OGTT).

Conditions

• Hypomagnesemia
• Kidney Transplantation

Interventions

Type	Name	Description
DRUG	Mablet 360 mg	Slow-released magnesium hydroxide
DRUG	Placebo	Placebo

Timeline

• Start date: 2020-02-25
• Primary completion: 2022-08-31
• Completion: 2022-08-31
• First posted: 2020-05-11
• Last updated: 2021-09-28

Locations

1 site across 1 country: Norway